Mentari Therapeutics, Inc. (MTRI) Stock Price & Analysis
Mentari Therapeutics, Inc. (MTRI) is trading at USD 15.11, down 13.48% today, as of November 18, 2026 at 20:48 UTC (US market open; quotes may be delayed), according to Nexqual market data.
MTRI last closed at USD 17.5; today's session has ranged USD 14.78–18.12 on volume of 214,194 shares. Market capitalization is $880.84M, with a 52-week range of USD 5.75–23.3 (NCM). Source: Nexqual, retrieved November 18, 2026 at 20:53 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MTRI.md
Key facts (MTRI)
- Insider open-market purchases, last ~7 months: 12 Form 4 filings, $1.4M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (2 analysts), mean target USD 33 (range 33–33).
- Total return with dividends: 1Y +3.5% vs S&P 500 +11.9%; 5Y -99.8% vs S&P 500 +66.7%.
- Next earnings: 2027-02-10 (date not yet confirmed by the company), EPS estimate USD —, revenue estimate $0K.
- Dividend: MTRI paid no cash dividend in the last five years.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MTRI)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.4M | $4.1M | $4.6M | $4.9M | — | — |
| Gross profit | $544K | $1.4M | $1.1M | $1.7M | — | — |
| Operating income | -$18.6M | -$7.9M | — | — | — | — |
| Net income | -$18.6M | -$7.9M | -$7.7M | -$8.2M | -$12.6M | -$13.2M |
| EPS (diluted) | -$6634.00 | -$650.00 | -$201.40 | -$83.60 | -$31.20 | — |
| Free cash flow | -$15.6M | -$7.4M | -$7.0M | — | — | — |
| Gross margin | 39.8% | 33.9% | 23.9% | 34.5% | — | — |
| Operating margin | -1361.9% | -192.2% | — | — | — | — |
| Net margin | -1361.9% | -192.2% | -166.9% | -165.1% | — | — |
| Revenue growth | -28.3% | +202.8% | +11.2% | +7.5% | — | — |
| Cash + short-term investments | $6.2M | $9.0M | $6.6M | $11.1M | $2.2M | — |
Fiscal years end Jun. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Sep 30, 2026) (MTRI)
Earnings yield -1.49%
Insider purchases (SEC Form 4, open-market, last ~7 months) (MTRI)
12 purchases, $1.4M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-11-05 | Adar1 Capital Management, Llc | 2,640 | $35K | 13.1 | Too little history (no open-market trades in 2023–2025) | |
| 2026-10-23 | Adar1 Capital Management, Llc | 4 | $0K | 1.32 | Too little history (no open-market trades in 2023–2025) | |
| 2026-10-16…2026-10-19 | Adar1 Capital Management, Llc | 1,087 | $1K | 1.32 | Too little history (no open-market trades in 2023–2025) | |
| 2026-10-13…2026-10-15 | Adar1 Capital Management, Llc | 9,569 | $13K | 1.33 | Too little history (no open-market trades in 2023–2025) | |
| 2026-10-06…2026-10-08 | Adar1 Capital Management, Llc | 10,903 | $14K | 1.33 | Too little history (no open-market trades in 2023–2025) | |
| 2026-10-01…2026-10-05 | Adar1 Capital Management, Llc | 42,920 | $57K | 1.33 | Too little history (no open-market trades in 2023–2025) | |
| 2026-09-14…2026-09-16 | Adar1 Capital Management, Llc | 91,101 | $118K | 1.3 | Too little history (no open-market trades in 2023–2025) | |
| 2026-07-14…2026-07-16 | Vivo Opportunity, Llc | 20,546 | $32K | 1.55 | Too little history (no open-market trades in 2023–2025) | |
| 2026-07-15 | Adar1 Capital Management, Llc | 1,000 | $2K | 1.55 | Too little history (no open-market trades in 2023–2025) | |
| 2026-06-30…2026-07-02 | Vivo Opportunity, Llc | 6,551 | $10K | 1.55 | Too little history (no open-market trades in 2023–2025) | |
| 2026-05-20…2026-06-08 | Vivo Opportunity, Llc | 249,227 | $392K | 1.57 | Too little history (no open-market trades in 2023–2025) | |
| 2026-05-19 | Adar1 Capital Management, Llc | 468,551 | $722K | 1.54 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (MTRI)
Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 33 (low 33, high 33).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-11-10 | Jefferies | Initiated | Buy | $30 |
| 2026-11-10 | Stifel | Initiated | Buy | $30 |
Total return (dividends reinvested) (MTRI)
| 1Y (from 2025-11-18) | 5Y (from 2021-11-15) | |
|---|---|---|
| Total return | +3.5% | -99.8% |
| S&P 500 (SPY) | +11.9% | +66.7% |
| Per year | +3.5% | -72.1% |
| Volatility (annualized) | 124.3% | 117.1% |
| Max drawdown | -57.9% (Nov 2025→Mar 2026) | -99.9% (Nov 2021→May 2026) |
Dividends (MTRI)
MTRI paid no cash dividend in the last five years.
MTRI major shareholder filing: Schedule 13D, Nov 12, 2026
Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Peter Evan Harwin filed a Schedule 13D with the SEC on Nov 12, 2026, reporting up to 19.99% of the class. A Schedule 13D is filed by an owner of more than 5% who may seek to influence the company. Item 4 (Purpose of Transaction), quoted from the filing:
The Reporting Persons own 19.99% of the Company in the aggregate, based upon the Company's aggregate outstanding shares as of November 6, 2026. The Reporting Persons' securities include 10,555,507 shares of Common Stock directly held by Fund II, and exclude (i) 4,013,000 shares of Common Stock issuable upon conversion of 4,013 shares of Series A Preferred Stock directly held by Fund II and (ii) 1,468,222 shares of Common Stock issuable upon exercise of Pre-Funded Warrants directly held by Fund II. The exercise of the Pre-Funded Warrants is subject to a beneficial ownership limitation of 19.99% of the outstanding shares of Common Stock and the conversion of the Series A Preferred Stock is subject to a beneficial ownership limitation of 19.99% of the outstanding shares of Common Stock. The securities exclude shares of Common Stock issuable upon exercise of Pre-Funded Warrants and conversion of Series A Preferred Stock in excess of such beneficial ownership limitations. At such time as Fairmount and its affiliates beneficially own 9.0% or less of the outstanding shares of Common Stock, the beneficial ownership limitation with respect to the Series A Preferred Stock will automatically reduce to 9.99%. …
Source: SEC EDGAR, Schedule 13D filed Nov 12, 2026. Quoted word for word; Nexqual adds no interpretation.
MTRI recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Nov 16, 2026 | Schedule 13G/A | Squadron Master Fund LP, Squadron Capital Management LLC: 0.0% of shares, passive 5%+ holder (amended) |
| Nov 16, 2026 | 8-K | Completed an acquisition or sale of assets; Quarterly results “Financial Information Unaudited Financial Statements The unaudited condensed consolidated financial statements of Mentari as of September 30, 2026 and for the three and nine months ended September 30, 2026 and related notes thereto are attached hereto as Exhibit 99.1 and incorporated herein by reference. Management's Discussion and Analysis of Financial Condition and Results of Operations Mentari's Management's Discussion and Analysis of Financial Condition and Results of Operations for the three and nine months…” |
| Nov 13, 2026 | Schedule 13G | Commodore Capital LP, Commodore Capital Master LP: 5.6% of shares, passive 5%+ holder |
| Nov 13, 2026 | Schedule 13G | Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd.: 5.6% of shares, passive 5%+ holder |
| Nov 12, 2026 | Schedule 13D | Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P.: 20.0% of shares, 5%+ holder that may seek to influence the company “The Reporting Persons own 19.99% of the Company in the aggregate, based upon the Company's aggregate outstanding shares as of November 6, 2026. The Reporting Persons' securities include 10,555,507 shares of Common Stock directly held by Fund II, and exclude (i) 4,013,000 shares…” |
| Nov 10, 2026 | 8-K | Entered a material agreement; Completed an acquisition or sale of assets; Quarterly results; Unregistered sale of shares; Change to shareholder rights; Change in control; Director or executive officer change, or pay arrangement; Bylaws or fiscal-year change; Code of ethics change or waiver; Item 5.06 “The information set forth under the headings " Contingent Value Rights Agreement " and " Registration Rights Agreement " in the Introductory Note of this Current Report on Form 8-K is incorporated by reference into this Item 1.01. Indemnification Agreements On November 6, 2026, the Company entered into indemnification agreements with each of its directors and executive officers (collectively, the " Indemnitees ," and such agreements, the " Indemnification Agreements "), which replaced and superseded any previous…” |
| Nov 9, 2026 | 8-K | Regulation FD disclosure |
| Nov 5, 2026 | 8-K | Regulation FD disclosure |
| Nov 5, 2026 | 8-K | Bylaws or fiscal-year change; Shareholder vote results; Other material event “On November 4, 2026, the Company held its Shareholders Meeting, at which the proposals set forth below, relating to the Merger Agreement and other matters, were submitted to the Company's shareholders. The proposals are described in detail in the Company's proxy statement/prospectus, dated October 1, 2026 and included as part of the Company's registration statement on Form S-4 (File No. 333-297234) (the "Proxy Statement"). There were 5,493,735 Common Shares outstanding and entitled to vote on September 25, 2026,…” |
| Nov 3, 2026 | 8-K | Regulation FD disclosure |
| Nov 3, 2026 | 10-Q | Quarterly report · period ended Sep 30, 2026 |
| Nov 2, 2026 | 425 | Merger or acquisition communication |
| Oct 27, 2026 | 425 | Merger or acquisition communication |
| Oct 7, 2026 | Schedule 13G/A | ADAR1 Capital Management, LLC, Daniel Schneeberger: 17.2% of shares, passive 5%+ holder (amended) |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
MTRI suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | BayMedica | “Since our inception, we have generated revenue from BayMedica product sales and no sales from any other sources and have incurred significant operating losses and negative cash flows from our operations.” |
Quoted from the company's 10-K filed Sep 9, 2026.
MTRI company outlook (results filed Nov 16, 2026)
- “The results for the three and nine months ended September 30, 2026 are not necessarily indicative of results that may be expected for the year ending December 31, 2026 or any other interim period or for any future year.”
- “F-11 vesting conditions, the expected term of the Company's stock options has been determined utilizing the "simplified" method for awards that qualify as "plain-vanilla" stock options.”
- “The grant dates for the issuance of warrants were expected to be December 31, 2025 and December 31, 2026 (if the term with respect to all Research Programs is still active), respectively, as all terms of the award, including number of shares and exercise price, will be known by all parties by this date.”
- “As of September 30, 2026, total unrecognized compensation cost related to the unvested RSAs was $0.1 million, which is expected to be recognized over a weighted average period of 2.9 years.”
Quoted word-for-word from the SEC 8-K results press release.
MTRI analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends Jun 2027) | $-1.75 | $0.00 | −$1.75 | $0 | 1 |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of November 18, 2026 at 20:53 UTC)
| Price | USD 15.11 |
|---|---|
| Change | ▼ 13.48% (down) |
| Previous Close | USD 17.5 |
| Open | USD 18.12 |
| Day Range | USD 14.78 – 18.12 |
| 52-Week Range | USD 5.75 – 23.3 |
| Volume | 214,194 shares |
| Market Cap | $880.84M |
| Exchange | NCM |
Technical Analysis (MTRI)
Nexqual's technical model rates MTRI "NEUTRAL" based on 2 bullish and 3 bearish signals across 129 daily candles, as of November 18, 2026 at 20:53 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 48.49 (neutral) |
| vs SMA50 | Above (USD 14.47) |
| MACD | 0.78 (positive) |
Analyst Ratings (MTRI)
Wall Street analysts rate MTRI "Buy" based on 2 analysts, with a mean price target of USD 33 (range USD 33–33), per Nexqual as of November 18, 2026 at 20:53 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 33 |
| High Target | USD 33 |
| Low Target | USD 33 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (MTRI)
| Next Earnings Date | 2027-02-10 |
|---|
Source: Nexqual, November 18, 2026 at 20:53 UTC.
Financials & Fundamentals (MTRI)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
Source: Nexqual, November 18, 2026 at 20:53 UTC.
Financial Health Score (MTRI)
Nexqual rates Mentari Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of November 18, 2026 at 20:53 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% (last 12 months) |
| Balance Sheet | Mixed — No data |
| Cash Flow | Weak — Operating cash flow -$9M (FY ended Jun 2026, 10-K) |
| Efficiency | Critical — ROE not meaningful (negative equity); ROA -1008.1% (last 4 quarters, SEC) |
Ownership (MTRI)
| Insider Ownership | +0.12% |
|---|---|
| Institutional Ownership | +27.10% |
| Shares Outstanding | 58.30M |
Source: Nexqual, November 18, 2026 at 20:53 UTC.
Leadership (MTRI)
Mentari Therapeutics, Inc. is led by Gregory J. Divis, CEO & Director, per Nexqual as of November 18, 2026 at 20:53 UTC.
| CEO & Director | Gregory J. Divis |
|---|
From Mentari Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-09-09)
Key Strengths & Strategy (as disclosed to the SEC)
- Following the wind down of commercial operations, InMed's remaining activities have consisted of preclinical development of its Product Candidates, including INM-901 for Alzheimer's disease, INM-089 for dry Age-related Macular Degeneration or dry AMD, and INM-755 (cannabinol) cream.
- InMed has selected drug candidate INM-089, a proprietary small molecule analog of INM-088, for further preclinical development in the potential treatment of dry AMD.
- In 2023, the FDA approved two new treatments which are complement inhibitors for advanced stages of dry AMD (called geographic atrophy ("GA")).
- Syforvre® (pegcetacoplan), developed by Apellis Pharmaceuticals, was approved by the FDA in February of 2023 for the treatment of geography atrophy, the late stage of dry AMD.
Partnerships
- While previous business development initiatives have been unsuccessful, we are open to strategic partnership opportunities for INM-755 in EB and other itch-related skin conditions.
- However, progression of the program will only occur in partnership with a suitable collaborator.
Legal & Regulatory Risks (Item 1A, quoted)
- Any Product Candidates we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, thereby materially and adversely impacting our business.
- Increased scrutiny on drug pricing or changes in pricing regulations could restrict the amount that we are able to charge for our Product Candidates, which could adversely affect our revenue and results of operations.
- Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse, federal exclusion or debarment, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.
- Failure to comply with the FCPA, the CFPOA, and other global anti-corruption and anti-bribery laws could subject us to penalties and other adverse consequences.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BLTE | Belite Bio, Inc | USD 156.45 | ▼ 0.81% |
| KOD | Kodiak Sciences Inc | USD 97.7 | ▲ 0.93% |
| ORKA | Oruka Therapeutics, Inc. | USD 95.68 | ▼ 0.67% |
| IMVT | Immunovant, Inc. | USD 33.24 | ▲ 0.08% |
| AXSM | Axsome Therapeutics, Inc. | USD 133.89 | ▼ 1.52% |
| IBRX | ImmunityBio, Inc. | USD 6.7 | ▲ 6.95% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 20:53 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt